Corporate
News release
TopTOKYO, JAPAN – March 2, 2023 – Terumo Corporation (TSE: 4543) today announced that it will further drive its initiatives to promote a culture of diversity, equity, and inclusion (DE&I) as a Group. The company has newly selected four focus areas it will commit on a global scale.
Currently, various challenges surround healthcare, such as the super-aging population and the complexity of chronic diseases. The vision for Terumo’s 5-Year Growth Strategy (GS26) “From Devices to Solutions” represents the company’s aspiration to provide solutions to these challenges.
Kyo Nishikawa, Director and Group Managing Executive Officer, Chief Human Resources Officer (CHRO) comments, “Innovation which triggers transformational change of business model is inevitable in light of the paradigm shifts in healthcare. New ideas are often created through exchange of different opinions. Therefore, it is important to create an inclusive environment where even some wild ideas can be openly shared”.
In March 2022, the company established a Group-wide “DE&I Philosophy” to cultivate a culture of DE&I globally. In order to further promote DE&I, Terumo has identified focus areas to be worked on across the Group: "Associate Diversity, Equity and Belonging”, “Inclusive Leadership”, “Policies and Practices” and “Awareness and Communication”. Each Group company will advance their initiatives along the four new focus areas.
By strengthening the DE&I culture at Terumo, the company will further strive to fulfill its purpose to advance healthcare and enhance patients’ quality of life.
2. Inclusive Leadership
3. Policies and Practices
4. Awareness and Communication
Currently, various challenges surround healthcare, such as the super-aging population and the complexity of chronic diseases. The vision for Terumo’s 5-Year Growth Strategy (GS26) “From Devices to Solutions” represents the company’s aspiration to provide solutions to these challenges.
Kyo Nishikawa, Director and Group Managing Executive Officer, Chief Human Resources Officer (CHRO) comments, “Innovation which triggers transformational change of business model is inevitable in light of the paradigm shifts in healthcare. New ideas are often created through exchange of different opinions. Therefore, it is important to create an inclusive environment where even some wild ideas can be openly shared”.
In March 2022, the company established a Group-wide “DE&I Philosophy” to cultivate a culture of DE&I globally. In order to further promote DE&I, Terumo has identified focus areas to be worked on across the Group: "Associate Diversity, Equity and Belonging”, “Inclusive Leadership”, “Policies and Practices” and “Awareness and Communication”. Each Group company will advance their initiatives along the four new focus areas.
By strengthening the DE&I culture at Terumo, the company will further strive to fulfill its purpose to advance healthcare and enhance patients’ quality of life.
The Four Focus Areas and its Major Initiatives for 2023
1. Associate Diversity, Equity and Belonging
- Stimulate the creation of an ARG (Associate Resource Group*1) at each Group company.
2. Inclusive Leadership
- Set specific DE＆I related goals for each Global Executive Officer and ensure the execution.
3. Policies and Practices
- Review HR policies and practices at each Group company from DE&I perspectives.
4. Awareness and Communication
- Strengthen both internal and external communication regarding DE&I. For example, hosting an annual “Terumo DE&I Week”*2 across the Group.
*1 ARG is a voluntary, associate-led group with those who share a characteristic/interest (gender, LGBTQ, etc.).
*2 For 2023, initiatives such as video messages from the management team, speaker sessions about DE&I, and ARG events will be held globally on March 6 to 10.
About Terumo
Terumo (TSE: 4543) is a global leader in medical technology and has been committed to “Contributing to Society through Healthcare” for 100 years. Based in Tokyo and operating globally, Terumo employs more than 30,000 associates worldwide to provide innovative medical solutions in more than 160 countries and regions. The company started as a Japanese thermometer manufacturer, and has been supporting healthcare ever since. Now, its extensive business portfolio ranges from vascular intervention and cardio-surgical solutions, blood transfusion and cell therapy technology, to medical products essential for daily clinical practice such as transfusion systems, diabetes care, and peritoneal dialysis treatments. Terumo will further strive to be of value to patients, medical professionals, and society at large.